Found: 39
Select item for more details and to access through your institution.
Inhibitory Mechanism of 10-Hydroxy- trans-2-decenoic Acid (Royal Jelly Acid) Against Lipopolysaccharide- and Interferon-β-Induced Nitric Oxide Production.
- Published in:
- Inflammation, 2013, v. 36, n. 2, p. 372, doi. 10.1007/s10753-012-9556-0
- By:
- Publication type:
- Article
Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2019, v. 11, n. 1, p. 1, doi. 10.4084/MJHID.2019.007
- By:
- Publication type:
- Article
Anti‐myeloma potential of ruxolitinib in co‐existing JAK2V617F‐positive smouldering myeloma and polycythaemia vera.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 3, p. e114, doi. 10.1111/bjh.16533
- By:
- Publication type:
- Article
Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40271-4
- By:
- Publication type:
- Article
Specific Egg Yolk Immunoglobulin as a New Preventive Approach for Shiga-Toxin-Mediated Diseases.
- Published in:
- PLoS ONE, 2011, v. 6, n. 10, p. 1, doi. 10.1371/journal.pone.0026526
- By:
- Publication type:
- Article
Amyloidosis and COVID-19: experience from an amyloid program in Canada.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 10, p. 2307, doi. 10.1007/s00277-022-04964-y
- By:
- Publication type:
- Article
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 10, p. 2521, doi. 10.1007/s00277-021-04591-z
- By:
- Publication type:
- Article
Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-09555-6
- By:
- Publication type:
- Article
The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 3, p. 340, doi. 10.1111/ejh.13552
- By:
- Publication type:
- Article
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing.
- Published in:
- Life Science Alliance, 2023, v. 6, n. 1, p. 1, doi. 10.26508/lsa.202201543
- By:
- Publication type:
- Article
Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 10, p. e331, doi. 10.1016/j.clml.2023.07.004
- By:
- Publication type:
- Article
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 413, doi. 10.1016/j.clml.2023.03.009
- By:
- Publication type:
- Article
Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone.
- Published in:
- 2023
- By:
- Publication type:
- journal article
OAB-018: A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S12, doi. 10.1016/S2152-2650(21)02092-9
- By:
- Publication type:
- Article
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Mass cytometry reveals increase in marrow resident monocytes associated with response to daratumumab and pomalidomide.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e99, doi. 10.1016/j.clml.2019.09.162
- By:
- Publication type:
- Article
Expansion of effector memory CD27+ T cells and tolerogenic type 2 classical dendritic cells regulate myeloma patients' sensitivity to daratumumab & IMiDs.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e29, doi. 10.1016/j.clml.2019.09.044
- By:
- Publication type:
- Article
Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e22, doi. 10.1016/j.clml.2019.09.033
- By:
- Publication type:
- Article
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, n. 1, p. e69, doi. 10.1016/j.clml.2017.10.009
- By:
- Publication type:
- Article
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible MM.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e68, doi. 10.1016/j.clml.2017.03.123
- By:
- Publication type:
- Article
Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed by ASCT with Bor-HDM Conditioning Regimen: A Single Center Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e117, doi. 10.1016/j.clml.2017.03.213
- By:
- Publication type:
- Article
Absolute Lymphocyte Count and Immunoparesis: Impact on Clinical Outcomes for Non-transplant Eligible MM Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e114, doi. 10.1016/j.clml.2017.03.208
- By:
- Publication type:
- Article
Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e67, doi. 10.1016/j.clml.2017.03.122
- By:
- Publication type:
- Article
Revised International Staging System Applied to Real World Multiple Myeloma Patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
- Published in:
- 2016
- By:
- Publication type:
- journal article
IMPACT OF COVID-19 ON THE DIAGNOSIS AND MANAGEMENT OF MULTIPLE MYELOMA: EXPERIENCE FROM A CANADIAN CENTER.
- Published in:
- Clinical & Translational Investigation / Revista de Investigación Clínica, 2022, v. 74, n. 1, p. 16, doi. 10.24875/RIC.21000347
- By:
- Publication type:
- Article
In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 5, p. 1009, doi. 10.1007/s00280-009-0957-1
- By:
- Publication type:
- Article
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00710-9
- By:
- Publication type:
- Article
Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma.
- Published in:
- Journal of Pathology: Clinical Research, 2020, v. 6, n. 4, p. 252, doi. 10.1002/cjp2.168
- By:
- Publication type:
- Article
FACTORES Y NIVEL DE RIESGO PARA DIABETES MELLITUS TIPO 2 E HIPERTENSIÓN ARTERIAL EN UNA COMUNIDAD RURAL.
- Published in:
- Revista de la Alta Tecnología y Sociedad, 2017, v. 9, n. 4, p. 50
- By:
- Publication type:
- Article
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
- Published in:
- British Journal of Haematology, 2008, v. 143, n. 4, p. 520, doi. 10.1111/j.1365-2141.2008.07387.x
- By:
- Publication type:
- Article
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
- Published in:
- British Journal of Haematology, 2008, v. 141, n. 5, p. 598, doi. 10.1111/j.1365-2141.2008.07044.x
- By:
- Publication type:
- Article
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2006, v. 134, n. 1, p. 37, doi. 10.1111/j.1365-2141.2006.06122.x
- By:
- Publication type:
- Article
Glycochips from Polyanionic Glycopolymers as Tools for Detecting Shiga Toxins.
- Published in:
- ChemBioChem, 2007, v. 8, n. 17, p. 2117, doi. 10.1002/cbic.200700439
- By:
- Publication type:
- Article
Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00636
- By:
- Publication type:
- Article
Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.
- Published in:
- Current Oncology, 2024, v. 31, n. 9, p. 5608, doi. 10.3390/curroncol31090415
- By:
- Publication type:
- Article
Inhibitory effect of 10-hydroxy-trans-2-decenoic acid on LPS-induced IL-6 production via reducing IκB-ζ expression.
- Published in:
- Innate Immunity, 2012, v. 18, n. 3, p. 429, doi. 10.1177/1753425911416022
- By:
- Publication type:
- Article